Table 3 Intraoperative characteristics and outcomes between Non-AKI group and AKI group stratified by age ≥ 65 years
Age < 65 years | Age ≥ 65 years | |||||||
|---|---|---|---|---|---|---|---|---|
Non-AKI group (n = 545) | AKI group (n = 19) | P | Chi-squared | Non-AKI group (n = 211) | AKI group (n = 21) | P | Chi-squared | |
Intraoperative characteristics | ||||||||
Nadir MAP (mmHg), mean ± SD | 71.83 ± 8.24 | 69.65 ± 12.41 | 0.469 | 70.72 ± 8.02 | 64.59 ± 12.06 | 0.033 | ||
Hypotension, n(%) | 102 (18.7%) | 7 (36.8%) | 0.070 | 43 (20.4%) | 12 (57.1%) | 0.001 | ||
Norepinephrine use, n(%) | 50 (9.2%) | 2 (10.5%) | 0.692 | 22 (10.4%) | 7 (33.3%) | 0.008 | ||
Dopamine use, n(%) | 14 (2.6%) | 0 (0) | 1.000 | 2 (0.9%) | 1 (4.8%) | 0.249 | ||
Milrinone use, n(%) | 56 (10.3%) | 3 (15.8%) | 0.437 | 35 (16.6%) | 3 (14.3%) | 1.000 | ||
Received red blood cell, n(%) | 49 (9.0%) | 2 (10.5%) | 0.686 | 27 (12.8%) | 9 (42.9%) | 0.001 | ||
Received plasma, n(%) | 30 (5.5%) | 2 (10.5%) | 0.294 | 15 (7.1%) | 7 (33.3%) | 0.001 | ||
Crystalloid (ml), Median [25th to 75th P] | 1400 [1000–1500] | 1500 [1000–2000] | 0.057 | 1500 [1000–1500] | 1500 [1000–2325] | 0.061 | ||
Hydroxyethyl starch (ml), Median [25th to 75th P] | 500 [500–500] | 500 [500–500] | 0.950 | 500 [500–563] | 500 [500–1000] | 0.119 | ||
Blood loss (ml), Median [25th to 75th P] | 200 [100–300] | 200 [50–400] | 0.357 | 200 [100–325] | 500 [150–1150]] | 0.016 | ||
Urine volume (ml), Median [25th to 75th P] | 300 [200–500] | 400 [250–600] | 0.468 | 400 [200–600] | 500 [250–800] | 0.068 | ||
Clamping of portal vein times (n), Median [25th to 75th P] | 1 [1–2] | 1.5 [1–2] | 0.933 | 1 [1–2] | 2 [1–2.5] | 0.297 | ||
Clamping of portal vein duration (min), Median [25th to 75th P] | 25 [15–30] | 25 [16–29] | 0.959 | 20 [15–30] | 20 [17–43] | 0.586 | ||
Surgery duration (hours), Median [25th to 75th P] | 3.0 [2.5–4.0] | 4.0 [3.0–4.5] | 0.033 | 3.5 [2.5–4.5] | 4.0 [3.3–5.0] | 0.030 | ||
Postoperative laboratory characteristics | ||||||||
Peak AST (IU/L), Median [25th to 75th P] | 174 [101–331] | 310 [162–718] | 0.066 | 164 [103–264] | 298 [140–800] | 0.005 | ||
Peak ALT (IU/L), Median [25th to 75th P] | 192 [113–371] | 272 [181–600] | 0.031 | 155 [96–282] | 266 [128–1052] | 0.008 | ||
Peak sCr (μmol/L), Median [25th to 75th P] | 62.4 [51.7–75.0] | 90.0 [67.2–141.0] | < 0.001 | 66.0 [56–80.0] | 95.0 [74.8–136.5] | < 0.001 | ||
Minimum eGFR (ml/min/1.73m2), Median [25th to 75th P] or mean ± SD | 89.7 [74.5–108.1] | 62.3 [42.2–72.4] | < 0.001 | 68.67 ± 17.66 | 46.59 ± 18.08 | < 0.001 | ||
Peak BUN (μmol/L), Median [25th to 75th P] | 5.5 [4.6–6.5] | 6.3 [5.2–8.8] | 0.009 | 6.4 [5.3–7.5] | 7.4 [5.6–13.1] | 0.029 | ||
ICU admission, n(%) | 27 (5.0%) | 0 (0) | 1.000 | 19 (9.0%) | 7 (33.3%) | 0.004 | ||
Hospital length of stay (days), Median [25th to 75th P] | 11 [9–14] | 13 [9–15] | 0.505 | 13 [10–15] | 16 [11–26] | 0.028 | ||
Re-operation, n(%) | 3 (0.6%) | 1 (5.3%) | 0.128 | 1 (0.5%) | 0 (0) | 1.000 | ||
Mortality, n(%) | 1 (0.2%) | 0 (0) | 1.000 | 1 (0.5%) | 1 (4.8%) | 0.173 | ||